Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the latest clinical study with VagiVital® has been published. The objective of the study was to investigate whether, and to what extent, VagiVital® can relieve symptoms associated with vaginal atrophy in women taking aromatase inhibitors (antiestrogens) as part of their cancer treatment.
The study shows that VagiVital® offers strong relief of the most bothersome symptoms such as vaginal dryness, vaginal itching and pain during sexual intercourse (dyspareunia). In addition, vaginal pH decreased as a result of treatment with VagiVital®. All improvements were statistically significant (p<0.001) and the magnitude of the improvements were at least on the same level as seen in previous clinical studies with VagiVital®. To read the study please click dovepress.com/an-open-uncontrolled-pilot-study-on-12-week-use-of-vagivital-for-treat-peer-reviewed-fulltext-article-MDER
The study was conducted on a group of women with, in many cases, severe symptoms due to their medication and Peptonic is very pleased to be able to offer a hormone-free symptom relief with clinically proven effect to this group.
The study was conducted at Karolinska University Hospital and lasted for 12 weeks with a 2-week follow-up. The study patient population consisted of 28 women aged 40 to 82 years, all of whom had been treated for hormone-dependent cancer and were on treatment with aromatase inhibitors, and suffered from symptoms of vaginal atrophy. These women are contraindicated for estrogens and other hormones.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
About Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative biomedical company that conducts research on and development of drugs and medical devices in the field of women’s health. Our vision is to offer safe and effective treatments for women-specific diseases and medical conditions. Peptonic Medical launched VagiVital® in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness. The company’s development program also includes Vagitocin® – a product that contains oxytocin for the treatment of vaginal atrophy. The development of Vagitocin® has been put on hold pending new information regarding the mechanism of action of oxytocin in this indication. The company was founded in 2009 and the share has been traded since 2014 on Spotlight (www.spotlightstockmarket.com, short code: PMED) in Stockholm.
Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical. Lune Group Oy Ltd. is a company founded by Heli Kurjanen in 2005. The company’s business concept is to lead a menstrual revolution in a positive spirit. By focusing on sustainable development, environmental issues and the promotion of sexual health, the company has developed to take the lead for the menopausal companies. Lunette® menstrual cups are an alternative to disposable menstrual protection and last for several years. The company has resellers in 50 countries and sells Lunette products to over 100 countries via its web shop. Lune Group has in the USA the subsidiary Lune North America Inc. Lunette® menstrual cups are designed, manufactured and packaged in Finland. For more information about Lunette®, visit www.lunette.com.